# Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies

> **NCT01045421** · PHASE1,PHASE2 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 273 (actual)

## Conditions studied

- Advanced Nonhematological Malignancies
- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer
- Metastatic Breast Cancer
- Head and Neck Squamous Cell Carcinoma
- Gastroesophageal Adenocarcinoma

## Interventions

- **DRUG:** MLN8237 (Alisertib)

## Key facts

- **NCT ID:** NCT01045421
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2013-05
- **Final completion:** 2014-04
- **Target enrollment:** 273 (ACTUAL)
- **Last updated:** 2016-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01045421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01045421, "Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01045421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*